Investigational Drug Information for Arimoclomol
✉ Email this page to a colleague
What is the development status for investigational drug Arimoclomol?
Arimoclomol is an investigational drug.
There have been 10 clinical trials for Arimoclomol.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 31st 2018.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Orphazyme, University of Kansas Medical Center, and CytRx.
There are forty US patents protecting this investigational drug and eight hundred and twenty-four international patents.
Summary for Arimoclomol
US Patents | 40 |
International Patents | 824 |
US Patent Applications | 347 |
WIPO Patent Applications | 155 |
Japanese Patent Applications | 22 |
Clinical Trial Progress | Phase 3 (2018-07-31) |
Vendors | 34 |
Recent Clinical Trials for Arimoclomol
Title | Sponsor | Phase |
---|---|---|
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial | Orphazyme | Phase 3 |
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial | University College, London | Phase 3 |
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial | University of Kansas Medical Center | Phase 3 |
Clinical Trial Summary for Arimoclomol
Top disease conditions for Arimoclomol
Top clinical trial sponsors for Arimoclomol
US Patents for Arimoclomol
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Arimoclomol | ⤷ Sign Up | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | ⤷ Sign Up |
Arimoclomol | ⤷ Sign Up | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease | Axovant Sciences GmbH (Basel, CH) | ⤷ Sign Up |
Arimoclomol | ⤷ Sign Up | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | ENTERIN LABORATORIES, INC. (Merion, PA) | ⤷ Sign Up |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Arimoclomol
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Arimoclomol | Argentina | AR104982 | 2035-06-12 | ⤷ Sign Up |
Arimoclomol | Australia | AU2016276966 | 2035-06-12 | ⤷ Sign Up |
Arimoclomol | Australia | AU2021269398 | 2035-06-12 | ⤷ Sign Up |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |